Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

When Drugs Become Biologics: US FDA Guidances Explain 'Transition Provisions'

Dec 11 2018

• By Sue Sutter

The concept of order and chaos. Chaotic disorganized colorful paper clips and to order the yellow paper clip

Related Content

US FDA's Gottlieb Shuts The Door On Exclusivity For 'Transition' Biologics

Dec 11 2018

US FDA finalizes three biosimilars guidances

Apr 29 2015

Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested

May 18 2015

BLAs More Appealing As 'Transition' NDAs, ANDAs Set To Lose Exclusivity

Mar 21 2016

FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear

May 23 2016

Additional Topics

United States Biosimilars Biologics Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window